Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity.
about
Airway fibrinogenolysis and the initiation of allergic inflammationPro/Con debate: Is occupational asthma induced by isocyanates an immunoglobulin E-mediated disease?IgE-based Immunotherapy of Cancer -A Comparative Oncology ApproachThe discovery of IgE 50 years later.Development of mast cells and importance of their tryptase and chymase serine proteases in inflammation and wound healing.Penicillin allergy and the heterogenous immune responses of man to benzylpenicillin.IgE secretion by Epstein-Barr virus-infected purified human B lymphocytes is stimulated by interleukin 4 and suppressed by interferon gammaDecreased prevalence of asthma among children with high exposure to cat allergen: relevance of the modified Th2 responseAtopic dermatitis: a paradigmatic allergic skin disease.Serum IgE in asthmatic children. Relation to age, sex, eczema, and skin sensitivity tests.IgE concentrations in allergic asthma in children.Allergic inflammation--innately homeostaticAntibodies-structure and biological functionMast cells and company.Bronchial asthma: lessons from murine modelsAntigen-induced bronchial anaphylaxis in actively sensitized guinea-pigs: anti-anaphylactic effects of sodium cromoglycate and aminophyllineThe recent history of the treatment of asthma: a personal view.Atopic Dermatitis: A Cross-Sectional (Descriptive) Study of 100 CasesDistribution of allergy in a population sample residing in Tucson, ArizonaSpecificity of fixation loci for homocytotropic antibodiesAllergy-induced preterm labor after the ingestion of shellfish.Incrimination of Blomia tropicalis as a Potent Allergen in House Dust and Its Role in Allergic Asthma in Kolkata Metropolis, India.IgE antibodies, FcεRIα, and IgE-mediated local anaphylaxis can limit snake venom toxicity.Interleukin 13 and the evolution of asthma therapy.Human reagins: appraisal of the properties of the antibody of immediate-type hypersensitivity.Emerging therapies for food allergy.IgE and mast cells in allergic disease.Immunoglobulin E, what is it good for?From IgE to Omalizumab.Current and future applications of the anti-IgE antibody omalizumab.Reagin-like activity of serum in human peridonotal disease.Measurement of total IgE antibody levels in lacrimal fluid of patients suffering from atopic and non-atopic eye disorders. Evidence for local IgE production in atopic eye disorders?Allergen-independent immunomodulatory activities of immunoglobulin E.Two unusual forms of human immunoglobulin E encoded by alternative RNA splicing of epsilon heavy chain membrane exons.The Fab fragment of anti-IgE Cε2 domain prevents allergic reactions through interacting with IgE-FcεRIα complex on rat mast cells
P2860
Q26851613-865679EF-2F2B-46E8-8207-BB91CEA2DE02Q28389701-F4B5C2B0-C68B-4073-BD84-3B0DE785D32CQ28655505-6586B724-64AA-468F-8C8E-B5B6C896BF2EQ30277204-4C57B281-364D-4208-BF1D-4DBD43D5E5F5Q33969412-F13B5FB7-A2FF-4A57-9843-CF53AA89DC2BQ34086083-458F695F-15DA-4410-89D9-2369BE59B13EQ34292243-5CF98A17-F08D-4BF4-88E3-758EC89B00E5Q34510803-771D4F42-DA06-402F-B37C-5E20ABAD4C7FQ34510809-6D37CF15-3CC1-4DE0-9DB2-F5D59C368FD4Q35150463-0362BCF4-6B09-4DFB-9917-F106DA30A554Q35150879-9CF6EA20-EC87-479D-B009-72FE14702314Q35164318-86645C01-00CF-46CF-BFCB-C5001472B577Q35860568-AC9D1269-B358-4D87-9DBE-799DA797A742Q35927793-A4BD90F4-94D1-46B8-9809-006314BAC66AQ36002844-882B2BB8-A173-4FC2-B474-56E31575F84DQ36096742-16FFFE91-C2D2-4117-A38A-F8275D7ACCB1Q36127360-FF8D6D7A-8BFB-4706-8F01-3F8EA636934EQ36147769-36F78C11-8425-411A-BCB1-57392AF43B7EQ36201220-5A2181C7-9C3D-4C24-91C0-899E08AF59D1Q36271213-150F5A55-6D54-4C22-A0F4-D3823CC19A46Q36321497-C3BBCFB3-B485-4543-984C-75F0D444E210Q36370895-EAC5E51F-AF7B-41C5-AA1B-468AC2FCD612Q36469735-230467E5-E6F5-47F3-913E-DA2B140862D6Q36777718-6AACC181-EE33-46B5-8E41-82B26C108D44Q37200872-E8CB9B79-4995-4BD0-80B7-1FDF3D195190Q37726651-04726EB4-306C-4F92-942C-E7BBB8DCDD75Q38007829-BF4A61F8-CDBA-482D-B5D6-A2318D7CBCB2Q38761823-F5DB6C38-9DE7-435B-B934-542994B3193EQ38793428-BE2DFEA8-51E0-4FBC-B9B6-CB12665ED75AQ40119246-D48B7BF6-EB5C-44E1-8E03-9E04735A9223Q40908521-2C87DD90-9B00-4F9B-A4EE-0EA8A59049A5Q42612911-5CFFA1A8-D697-404E-93D1-1787C4BC6FBAQ42761747-CE196A86-FF98-4284-AF8E-56F4958EB592Q42768980-872A4009-B4F6-46B9-A3E7-B932BFAD7F4AQ58700697-CD428104-9456-49BF-9D6B-1A21F487CD4B
P2860
Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity.
description
1966 nî lūn-bûn
@nan
1966 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1966 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1966年の論文
@ja
1966年論文
@yue
1966年論文
@zh-hant
1966年論文
@zh-hk
1966年論文
@zh-mo
1966年論文
@zh-tw
1966年论文
@wuu
name
Physico-chemical properties of ...... carrier of reaginic activity.
@ast
Physico-chemical properties of ...... carrier of reaginic activity.
@en
Physico-chemical properties of ...... carrier of reaginic activity.
@nl
type
label
Physico-chemical properties of ...... carrier of reaginic activity.
@ast
Physico-chemical properties of ...... carrier of reaginic activity.
@en
Physico-chemical properties of ...... carrier of reaginic activity.
@nl
prefLabel
Physico-chemical properties of ...... carrier of reaginic activity.
@ast
Physico-chemical properties of ...... carrier of reaginic activity.
@en
Physico-chemical properties of ...... carrier of reaginic activity.
@nl
P2093
P1476
Physico-chemical properties of ...... carrier of reaginic activity.
@en
P2093
Hornbrook MM
Ishizaka K
Ishizaka T
P407
P577
1966-07-01T00:00:00Z